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Background:Aortic valve replacement for calciﬁc aortic valve stenosis is one of themore common cardiac surgical
procedures. However, the underlying pathophysiology of calciﬁc aortic valve stenosis is poorly understood. We
therefore investigated the histologic ﬁndings of aortic valves excised for calciﬁc aortic valve stenosis and corre-
lated these ﬁndings with their associated clinical features.
Results and Methods: We performed a retrospective analysis on 6685 native aortic valves excised for calciﬁc
stenosis and 312 prosthetic tissue aortic valves with calciﬁc degeneration at a single institution between 1987
and 2013. Patient demographics were correlated with valvular histologic features diagnosed on formalin-ﬁxed,
decalciﬁed, and parafﬁn embedded hematoxylin and eosin stained sections. Of the analyzed aortic valves,
5200 (77.8%) were tricuspid, 1473 (22%) were bicuspid, 11 (0.2%) were unicuspid, and 1 was quadricuspid. The
overall prevalence of osseous and/or chondromatous metaplasia was 15.6%. Compared to tricuspid valves, bicuspid
valves had a higher prevalence of metaplasia (30.1% vs. 11.5%) and had an earlier mean age of excision (60.2 vs. 75.1
years old). In addition, the frequency of osseous metaplasia and/or chondromatous metaplasia increased with age at
time of excision of bicuspid aortic valves, while tricuspid aortic valves showed the same incidence regardless of patient
age.Males had ahigher prevalence ofmetaplasia in both bicuspid (33.5% vs. 22.3%) and tricuspid (13.8% vs. 8.6%) aortic
valves compared to females. Osseousmetaplasia and/or chondromatousmetaplasiawas alsomore common in patients
with bicuspid aortic valves and concurrent chronic kidney disease or atherosclerosis than in those without (33.6% vs.
28.3%). No osseous or chondromatousmetaplasia was observedwithin the cusps of any of the prosthetic tissue valves.
Conclusions:Osseous and chondromatousmetaplasia are commonﬁndings in native aortic valves but donot occur
in prosthetic tissue aortic valves. Bicuspid valves appear to have an inherent proclivity formetaplasia, as demon-
strated by their higher rates of osseous metaplasia and/or chondromatous metaplasia both overall and at earlier
age compared to tricuspid and prosthetic tissue aortic valves. This predilection could be due to aberrant hemo-
dynamic forces on bicuspid valves, as well as intrinsic genetic changes associated with bicuspid valve
formation. Aortic valve interstitial cells may play a central role in this process. Calciﬁcation of prosthetic tissue
valves is most likely a primarily dystrophic phenomenon.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aortic stenosis affects 12% of the elderly population, is associated
with a 1.8-fold higher rate of mortality than age- and sex-matched
controls, and is one of themost common indications for cardiac surgery
[1,2]. Historically, aortic valve (AV) calciﬁcationwas considered to be an
entirely passive phenomenon attributed to accumulated “wear and
tear.” It is now acknowledged that there can also be an active process
of bone formation in advanced lesions [3], as demonstrated by the
expression of bone-metabolizing proteins and the presence of osseous
metaplasia (OM) and chondromatous metaplasia (CM) within the AV.d in the study “Osseous and
is.”
righam and Women's Hospital,
13.
Mitchell).
. This is an open access article underThis metaplasia, observed in approximately 13% of resected AVs, is
a late histologic ﬁnding in the progression of aortic sclerosis to aortic
stenosis [4], and its clinical signiﬁcance is unknown.
In addition, the pathophysiology underlying OM and CM within
valves resected for calciﬁc AV stenosis (CAVS) is unclear, particularly
the metaplastic cell of origin. The source could be native valvular inter-
stitial cells (VICs) that undergo transdifferentiation and/or circulating
mesenchymal stem cells. VICs are a heterogenous group of cells that
collectively comprise the majority of the cellular population of the AV
and are responsible for maintaining valvular homeostasis. Furthermore,
these cells can transform to an osteogenic phenotype when exposed to
a variety of signals [5]. There is also evidence that circulating stem/
precursor cells that can differentiate to cells of themesenchymal lineage,
including osteocytes and chondrocytes, contribute to heterotopic ossiﬁ-
cation in ﬁbrodysplasia ossiﬁcans progressiva [6] and atherosclerosis
[7]. Bone marrow-derived hematopoietic cells have been shown to
populate the AV [8,9].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Age of resection in AVs resected for CAVS
Age Unicuspid Bicuspid Tricuspid Quadricuspid
b50 7 245 63 0
50–59 3 401 272 0
60–69 1 534 894 1
70–79 0 237 2134 0
80–89 0 56 1715 0
90+ 0 0 122 0
19M. Torre et al. / Cardiovascular Pathology 25 (2016) 18–24Bicuspid aortic valves (BAVs) tend to be resected for CAVS at an
earlier age compared to tricuspid aortic valves (TAVs) [10]. If there is a
difference in the prevalence of OM and CM between BAVs and TAVs,
this would suggest potentially distinct mechanisms underlying this
metaplasia and would also have implications for understanding CAVS.
In this study, we performed a retrospective chart review on approxi-
mately 7000 consecutive native AV specimens from patients with CAVS
and prosthetic tissue AVs with calciﬁc degeneration that were resected
over more than two decades at a single institution to determine
clinical–pathologic associations, including the incidence of TAV versus
BAV and any associated OM or CM.
2. Methods
This investigationwas a retrospective chart review study. Native and
prosthetic tissue AV resection cases were identiﬁed from the pathology
archives of Brigham andWomen's Hospital, a tertiary care hospital with
a high volume of cardiac surgery, between 1987 and 2013 (n=8164).
AV resection was performed in response to valvular dysfunction/
symptomatic stenosis and not the degree of calciﬁcation. Cases that
did not show evidence of calciﬁc stenosis or degeneration, had an
unknown number of cusps, or had active endocarditis were excluded.
Prosthetic tissue AVs of unspeciﬁed origin (i.e., porcine, bovine, homo-
graft) or with unknown implantation–resection interval were also
excluded. Six thousand nine hundred ninety-seven remaining cases
(6685 native AVs, 312 prosthetic tissue AVs) were then individually
assessed for (a) patient clinical information, such as age at time of resec-
tion, sex, number of aortic cusps, presence of atherosclerosis (deﬁned asTable 2
Clinical information and correlation with histologic ﬁndings in AVs resected for CAVS
Total
Unicuspid Number (%) 11
Age 45.2
# OM/CM (%) 3 (27.3%)
# Athero/CKD (%) 0 (0%)
# Athero/CKD with OM/CM (%) 0 (0%)
# Without athero/CKD with OM/CM (%) 3 (23%)
Bicuspid Number (%) 1473
Age 60.2
# OM/CM (%) 444 (30.1%)
# Athero/CKD (%) 509 (34.6%)
# Athero/CKD with OM/CM (%) 171 (33.6%)
# Without athero/CKD with OM/CM (%) 273 (28.3%)
Pb .04
Tricuspid Number (%) 5200
Age 75.1
# OM/CM (%) 597 (11.5%)
# Athero/CKD (%) 3564 (68.5%
# Athero/CKD with OM/CM (%) 411 (11.5%)
# Without athero/CKD with OM/CM (%) 186 (11.4%)
P=.86
Quadricuspid Number (%) 1
Age 62
# OM/CM (%) 0 (0%)
# Athero/CKD (%) 0 (0%)
# Athero/CKD with OM/CM (%) 0 (0%)
# Without athero/CKD with OM/CM (%) 0 (0%)
Athero, atherosclerosis.having at least one preoperative lesion within the coronary or carotid
arteries with ≥50% luminal stenosis, or presence of clinically signiﬁcant
peripheral vascular disease), and history of chronic kidney disease
(CKD) and (b) presence of OM and/or CM diagnosed on formalin-
ﬁxed, decalciﬁed, parafﬁn-embedded hematoxylin and eosin (H&E)
stained sections. Aortic valves were processed in a standardized fashion
for routine histologic evaluation: following formalin ﬁxation and acid
decalciﬁcation, a representative cross-section of each cusp (including
areas with the greatest extent of calciﬁcation) was taken from the free
edge to the annulus. H&E-stained slides were diagnosed by one of the
staff surgical pathologists. To examine epidemiological trends, cases
were grouped into tertiles based on year of excision/resection:
1987–1995, 1996–2004, and 2005–2013. Statistical analyses were per-
formed to determine associations between clinical characteristics and
rate of metaplasia and to make comparisons between groups. The
Student's t test was used to compare means; the chi-square test or
Fischer's Exact Test was used to compare proportions. P values b .05
were considered statistically signiﬁcant.
3. Results
Tables 1–3 present the major ﬁndings. Representative gross and
histologic images can be seen in Fig. 1.
3.1. Native AVs
There were 5200 TAVs and 1473 BAVs, representing 77.8% and 22%
of all native AV resection cases for CAVS, respectively. The mean age at
time of excision for BAVs was approximately 15 years earlier than that
for TAVs (60.2 vs. 75.1 years old, Pb .0001). Fig. 2A shows the distribu-
tion of ages. TAVs were associated with a higher rate of atherosclerosis
and/or CKD (68.5% vs. 34.6%, Pb .0001).
The overall male:female ratio of AV resection patientswas 1.4:1. The
imbalancewasmore pronounced for BAVs than for TAVs (2.4:1 vs. 1.2:1,
male:female, Pb .0001). Age at time of excision was younger in males
than in females for both BAVs (59.4 vs. 62.3 years old, Pb .0001) and
TAVs (74.3 vs. 76.1 years old, Pb .0001).Male Female Gender comparison
6 (54.5%) 5 (45.5%)
41.7 49.4 P=.13
2 (33.3%) 1 (20%) PN .99
0 (0%) 0 (0%)
0 (0%) 0 (0%)
2 (25%) 1 (20%) PN .99
1034 (70.2%) 439 (29.8%)
59.4 62.3 Pb .0001
346 (33.5%) 98 (22.3%) Pb .0001
404 (37.3%) 105 (23.9%) Pb .0001
144 (35.6%) 27 (25.7%) P=.55
202 (32.1%) 71 (21.3%) Pb .001
P=.23 P=.34
2868 (55.2%) 2332 (44.8%)
74.3 76.1 Pb .0001
396 (13.8%) 201 (8.6%) Pb .0001
) 2197 (76.6%) 1367 (58.6%) Pb .0001
304 (13.8%) 107 (7.8%) Pb .0001









Age of resection and metaplasia in AVs resected for CAVS
Age % Metaplasia # OM only # CM only # OM & CM #Without Metaplasia
Unicuspid
b50 28.7% 2 0 0 5
50–59 33.3% 1 0 0 2
60–69 0% 0 0 0 1
70–79 – 0 0 0 0
80–89 – 0 0 0 0
90+ – 0 0 0 0
Bicuspid
b50 19.7% 43 4 1 197
50–59 27.7% 94 7 10 290
60–69 33.5% 160 13 9 352
70–79 34.2% 69 5 7 156
80–89 39.3% 18 3 1 34
90+ – 0 0 0 0
Tricuspid
b50 12.7% 6 2 0 55
50–59 12.5% 31 3 0 238
60–69 11.4% 89 7 6 792
70–79 10.9% 197 27 8 1902
80–89 12.1% 179 13 16 1507
90+ 10.7% 13 0 0 109
Quadricuspid
b50 – 0 0 0 0
50–59 – 0 0 0 0
60–69 0% 0 0 0 1
70–79 – 0 0 0 0
80–89 – 0 0 0 0
90+ – 0 0 0 0
20 M. Torre et al. / Cardiovascular Pathology 25 (2016) 18–24The combined prevalence of OM and/or CM was 15.6%. BAVs had
more than a twofold higher incidence of metaplasia than TAVs (30.1%
vs. 11.5%, Pb .0001), and the incidence of metaplasia progressively
increased with age at time of excision in BAVs (19.7% age b50, 27.7%
age 50–59, 33.5% age 60–69, 34.2% age 70–79, 39.3% age 80–89) but
not in TAVs (12.7% age b50, 12.5% age 50–59, 11.4% age 60–69, 10.9%
age 70–79, 12.1% age 80–89, 10.7% age 90+), Table 2, Fig. 2B.
Males had a higher prevalence of OM and/or CM in BAVs (33.5% vs.
22.3%, Pb .0001) and TAVs (13.8% vs. 8.6%, Pb .0001) compared to
females. Concurrent atherosclerosis and/or CKD was associated with
an overall increase in prevalence of metaplasia in BAVs (33.6% vs.
28.3%, Pb .04) but not TAVs.
Quadricuspid (n=1) and unicuspid AVs (n=11) were rare.
Unicuspid AVs had an average age of resection of 45.2 years, a
male:female ratio of 1.2:1, and an overall prevalence of OM and/or CM
of 27.3%; although male sex was associated with earlier mean age of
excision and higher mean prevalence of metaplasia in unicuspid AVs,
these associationswere not statistically signiﬁcant. No case of unicuspid
AV had concurrent atherosclerosis or CKD. A quadricuspid AV was
resected from a 62-year-old male. Metaplasia was not identiﬁed in
this valve, nor was there concurrent atherosclerosis or CKD.
Comparing data from excision year tertiles revealed several epide-
miological changes. AV replacement for CAVS at Brigham andWoman's
Hospital increased in frequency over time. 1050, 2224, and 3399 TAVs
and BAVs were excised between 1987–1995, 1996–2004, and
2005–2013, respectively. In addition, the earliest tertile was associated
with a younger mean age at time of surgery compared to the two
more recent tertiles (70.2, 71.8, and 72.3 years old for the ﬁrst, second,
and third tertiles, respectively; Pb .001 for both comparisons). There
were no consistent and signiﬁcant changes in the proportion of BAVs,
prevalence of atherosclerosis or CKD, or sex ratio over time.
3.2. Prosthetic tissue AVs
There were 312 prosthetic tissue AVs (207 porcine, 67 bovine, and
38 homograft) resected with calciﬁc degeneration. The average intervalbetween implantation and resection was 10.9 years, ranging from
51 years to less than a year. Thirty-two prosthetic tissue AVs
(10.3%) were resected ≤5 years after implantation, 117 (37.5%) were
resected between 6 and 10 years after implantation, 127 (40.7%) were
resected between 11 and 15 years after implantation, 30 (9.6%) were
resected between 16 and 20 years after implantation, and 6 (1.9%)
were resected N20 years after implantation. Cuspal OM or CM was not
observed in any of the prosthetic tissue AVs.
There were no consistent and signiﬁcant differences in the number
of resected prosthetic tissue AVs, mean age at resection, or mean inter-
val between implantation and resection across tertiles. However, there
were shifts in prosthetic tissue AV type prevalence over time, with
porcine AVs decreasing in frequency and bovine and homograft AVs
increasing in frequency. Between 1987 and 1995, 99.1% of resected
prosthetic tissue AVs were porcine, and 0.9% were bovine. Between
1996 and 2004, 85.5% of resected prosthetic tissue AVs was porcine,
3.6% was bovine, and 10.8% was homografts. Between 2005 and 2013,
25.2% of resected prosthetic tissue AVs was porcine, 51.2% was bovine,
and 23.6% was homografts.
4. Discussion
This investigation represents the largest single study to date correlat-
ing patient clinical information and histologic ﬁndings in calciﬁed AVs.
The overall prevalence of metaplasia in resected native AVs was 15.6%,
which is similar to that reported by Mohler et al. [4]. However, due to
potential tissue sampling bias, we might be underreporting the actual
prevalence. In addition, we have demonstrated that the rate of OM and
CM varies with a number of clinical factors. This study (native AV,
n=6685) builds on the work by Roberts and Ko (n=932) [10], which
also observed that BAVs were resected earlier for calciﬁc stenosis than
TAVs. In contrast to their investigation, we found that that the mean
age at time of excision for BAVs was younger (60.2 vs. 67 years old).
Given (a) the observed difference in rates of metaplasia among BAVs,
TAVs, and prosthetic tissue AVs and (b) that calciﬁc stenosis/
degeneration is likely to progress via two pathways— dystrophic calciﬁ-
cation and osteogenic (i.e. metaplastic) calciﬁcation— the paradigm that
emerges is that of a spectrum in which the relative contribution of each
pathway to valvular disease varies by AV type. Calciﬁc degeneration in
prosthetic tissue AVs, which had no incidence of metaplasia, probably
occurs through a primarily dystrophic process. Meanwhile, calciﬁc
stenosis in BAVs, which had the highest rate of metaplasia, likely
progresses with the most robust osteogenic signaling. Because approxi-
mately 70% of BAVs did not have observable OM or CM, it should be
noted that a large degree of dystrophic calciﬁcation also contributes to
CAVS in BAVs. TAVs, with a rate of metaplasia between that of BAVs
and prosthetic tissue AVs, can be placed in themiddle of thismechanistic
spectrum. Fig. 3 illustrates this spectrum and summarizes the mecha-
nisms involved in dystrophic and osteogenic calciﬁcation.
The inherent proclivity of BAVs for developing OM and CM com-
pared to TAVs and prosthetic tissue AVs implicates the central roles of
VICs and aberrant hemodynamic and mechanokinetic forces in the
formation of cuspal metaplasia. The presence of two cusps compared
to three fundamentally alters the hemodynamic and mechanokinetic
forces experienced by the valve, which, along with oxidized lipids and
exogenous substances (e.g., bacterial lipopolysaccharide), can trans-
form quiescent VICs to activated VICs [11]. Activated VICs may undergo
osteogenic transdifferentiation. Importantly, it is conceivable that the
increase in incidence of metaplasia with age in BAVs is because older
valves have been exposed to these pathologic forces and the resultant
downstream signaling pathways for a greater period of time, increasing
the probability that metaplasia will occur.
Mechanistically, aberrant shear stress associated with BAVs results
in activation of the AV endothelium [increased expression of vascular
cell adhesion molecules (VCAM) and intercellular adhesion molecules
(ICAM)], up-regulation of bone morphogenetic protein 4 (BMP-4, a




Fig. 1.Aortic valve calciﬁcation andmetaplasia. (A–B) Gross images of resected tricuspid and bicuspid AVs demonstrating nodular calciﬁc deposits involving the outﬂow/aortic surfaces of
the valve cusps; (C) Gross photograph of an explanted Hancock porcine AV from the inﬂow aspect demonstrating calciﬁc degeneration with cuspal tears; (D–E) Typical calciﬁc degener-
ation demonstrating amorphous calciﬁc depositswith frequent neovascularization and chronic inﬂammatory inﬁltrate (H&E stain;40× objective); (F&I) Amorphous, focally punctate dys-
trophic calciﬁcation in explanted prosthetic tissue valveswithout associated osseous or chondromatousmetaplasia, neovascularization, or chronic inﬂammation (H&E stain;20× and 60×
objective); (G) OMwith osteoblastic activity, fatty marrow, and adjacent neovascularization with chronic inﬂammatory inﬁltrate (H&E stain;20× objective); (H) Combined osseous and
chondromatous metaplasia (H&E stain;40× objective).
21M. Torre et al. / Cardiovascular Pathology 25 (2016) 18–24proinﬂammatory osteogenicmorphogen) and TGF-beta, and promotion
of extracellularmatrix (EMC) remodeling that changes the stiffness of the
valve [12,13]. Altered valve stiffness exacerbates the supraphysiologic
forces on the valve. Activation of Toll-like receptors on VICs, possibly
from released double-stranded RNA from injured cells, increases expres-
sion of VIC expression of BMP-2 [14]. Exposure of VICs to BMP-2 increases
levels of Runx2 [15], a transcription factor that turns on osteoblast-related
gene expression, which is necessary for endochondrial bone formation,
and helps regulate the differentiation of chondrocytes and osteoblasts
[16]. BMP-2 also induces Sox9, another transcription factor that functions
to promote chondrogenesis [11].
VCAMand ICAMexpression stimulates inﬂammatory cell inﬁltration
of the valve, a process that is particularly exuberant in BAVs [17,18].
Chronic inﬂammation promotes angiogenesis, which is vital for bone
formation [19], as well as the release of TNF-alpha from activated leuko-
cytes. VICs exposed to TNF-alpha up-regulate expression of BMP-2 [20].
TGF-betamediates EMC remodeling [21] and stimulates productionof
reactive oxygen species (ROS). Oxidative stress,which is particularly high
in areas of AV calciﬁcation [22], can drive transformation of activatedVICs
to osteoblasts, possibly through Wnt3a signaling [23].
The particular susceptibility of BAVs to metaplasia might also have a
genetic foundation. The Notch1 pathway plays a role in organogenesis
and cell fate and functions to inhibit pro-osteoblastic signaling within
the AV. Mutations in Notch1 are associated with formation of BAVs, and
decreased levels of Notch1 result in higher VIC expression of BMP-2 [24].Dystrophic calciﬁcation in BAVs (and TAVs) might proceed via apo-
ptosis of VICs following valvular injury. This process is mediated in part
by TGF-beta [25] and valve stiffness [26].
In addition to our data, there is evidence suggesting that pro-
osteogenic signaling in TAVs is weaker than that in BAVs. Using an
ex vivo animal AV model, investigators showed that BAV-related hemo-
dynamics were associatedwith highermarkers of endothelial activation,
osteogenesis, and valvular remodeling than TAV-related hemodynamics
[12]. BAVs are exposed to higher biomechanical stress [27], which can
up-regulate BMP expression [28]. Pro-osteogenic signaling also pre-
sumably begins at a later age in TAVs compared to congenital BAVs.
If differentiation of circulating hematopoietic stem cells were central
to the development of OMandCM in theAV, the prevalence ofmetaplasia
should be similar between BAVs and TAVs. Nevertheless, circulating
marrow-derived cells have the capacity to home to areas of cell injury
[29] and have been found in areas of heterotopic ossiﬁcation [6,7],
including the stenotic AV, where BMPs and other substances may act
as possible recruitment signals [30]. As described previously, valvular
injury appears particularly robust in BAVs due to aberrant hemodynamic
and mechanokinetic forces.
The absence of metaplasia in the 312 resected prosthetic tissue AVs
is consistent with the characterization of calciﬁcation in prosthetic
tissue valves as a primarily dystrophic process. Bioprosthetic valves
are treated with glutaraldehyde, which increases tissue durability and
devitalizes AV connective tissue cells [31]. Extracellular calcium reacts
Fig. 2. (A) Distribution of age at excision for native bicuspid and tricuspid AVs excised for calciﬁc stenosis; (B) Rates of osseous and/or chondromatous with age in bicuspid and tricuspid AVs.
22 M. Torre et al. / Cardiovascular Pathology 25 (2016) 18–24withmembrane phosphate groups on residual devitalized cells, forming
calciﬁc nodules [31].
If metaplasia were seen in prosthetic tissue AVs, it would be highly
suggestive of circulating hematopoietic stem cells as the cell of originFig. 3.Mechanisms of calciﬁc stenosis and degeneration. Top: Simpliﬁed schematic outlining p
relative contributions of osteogenic and dystrophic pathways to calciﬁc stenosis and degenerafor OM and CM. Notably, there has been a case report of OM in a homo-
graft resected for valvular incompetence 6 years after implantation [32].
In this reported case by Lis et al., there were two foci of OM, one within
the wall of the sinus of Valsalva and the other in the hinge area of theathways likely underlying osteogenic and dystrophic calciﬁcation in the AV. Bottom: The
tion vary by AV type.
23M. Torre et al. / Cardiovascular Pathology 25 (2016) 18–24valve leaﬂet. We have observed metaplasia in the adjacent suture ring
material in four of the prosthetic tissue AV specimens. However, be-
cause this metaplasia did not occur in the valvular cusps themselves,
this was not identiﬁed as OM or CM within the prosthetic tissue valve.
Ultimately, there are several mutually nonexclusive reasons to ex-
plain the lack of OM and CM in bioprosthetic valves, including (a) the
devitalization of VICs, which would be unable to transdifferentiate to
osteocytes and chondrocytes; (b) an altered milieu unfavorable to the
recruitment and/or differentiation of circulating hematopoietic stem
cells; and (c) the interval between implantation and resection (average
of 10.9 years in our study) may be sufﬁcient for progression of dystro-
phic calciﬁcation but prohibitively brief for metaplastic transformation.
This study also demonstrates that presence of concurrent atheroscle-
rosis and/or CKD in BAVs and male sex for both BAVs and TAVs were as-
sociated with higher rates of metaplasia. Circulating lipids up-regulate
Wnt and BMP signaling [33], help drive osteoblastic differentiation [23],
and might also inactivate Notch1 [34]. The mechanisms underlying the
increased susceptibility of male AVs to develop metaplasia have yet to
be elucidated but implicate a role for hormonal modulation. Since
males also have a higher risk of developing vascular calciﬁcation and
atherosclerosis, this suggests that similar pathways might contribute to
these disease processes.
Lastly, because our data cover over two decades of AV excisions, we
have examined epidemiological trends. The patterns that we observed
in native AV cases, such as increasing surgical volume and older age at
time of excision, are in keeping with prior studies [35–37]. The shift
from porcine to bovine and homograft prosthetic tissue AVs might
reﬂect regional/institutional preferences as well as changes in surgical
practice following publication of reports suggesting better hemody-
namic function of bovine pericardial AVs compared to porcine
AVs [38,39]. However, such studies are not deﬁnitive, and prosthetic
tissue valve type does not appear to be associated with differences in
mortality [40,41].
5. Conclusion
The pathophysiology underlying OM and CM in AVs resected
for CAVS has not been fully elucidated. The higher prevalence of OM
and/or CM in native BAVs compared to TAVs suggests a central role of
VICs and aberrant hemodynamic and mechanokinetic forces in this
metaplasia. Circulating hematopoietic stem cells are much less likely
to be involved. Male sex and presence of atherosclerosis/CKD increase
the rate of metaplasia. Furthermore, cuspal number and sex inﬂuence
the age at which stenotic AVs are resected. Calciﬁcation in bioprosthetic
AVs appears to be due to a primarily dystrophic process. We propose a
theoretical paradigm in which the relative contribution of dystrophic
and osteogenic pathways varies by AV type.
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